ライフサイエンスコーパス: be planned

1 uate fund allocation for delivery of care to be planned.

2 hat acceptable alternative interventions can be planned.

3 A phase III study of palliative liver RT is planned.

4 ailure in men for whom radical prostatectomy is planned.

5 Radiation therapy is planned.

6 Further testing of this regimen is planned.

7 duction of diabetes if islet transplantation is planned.

8 candidate vaccine by intramuscular injection is planned.

9 antinib and erlotinib in patients with NSCLC is planned.

10 er clinical evaluation of pazopanib in NSCLC is planned.

11 yndromes for whom an early invasive strategy is planned.

12 ction or if highly immunosuppressive therapy is planned.

13 ants, especially when an NNRTI-based regimen is planned.

14 ase II study in resectable pancreatic cancer is planned.

15 rrently with routine immunization in infants is planned.

16 e is overt bleeding or an invasive procedure is planned.

17 ing CT with genomic and proteomic assessment is planned.

18 lticenter trial with patient-specific dosing is planned.

19 ia control into routine health-care delivery is planned.

20 f NSCLC patients for whom definitive therapy is planned.

21 is recommended especially if ptosis surgery is planned.

22 for patients in whom elective cardioversion is planned.

23 Continuation of the presented EQA scheme is planned.

24 dhood development and disability after pPROM is planned.

25 ermined and avoided in patients for whom BMT is planned.

26 lung disease and a placebo-controlled trial is planned.

27 charides bound to a medically useful carrier is planned.

28 A phase 2 study in young children is planned.

29 and patients blinded to treatment assignment is planned.

30 es, and a clinical trial of such a construct is planned.

31 ong-term follow-up of these immune responses is planned.

32 cal evaluation (if S. paratyphi A conjugates is planned.

33 examined when SED is assessed and treatment is planned.

34 t S. aureus bacteremia in this at-risk group is planned.

35 n patients with trauma and severe hemorrhage is planned.

36 opathy can occur later, so further follow-up is planned.

37 icentre, cluster randomised controlled trial is planned.

38 scale pivotal trials to confirm the approach are planned.

39 orrelative studies with molecular biomarkers are planned.

40 he racial disparities observed in this study are planned.

41 organ damage, and long-term end point trials are planned.

42 herapy in dosing schedules similar to adults are planned.

43 an earlier time window after stroke (<36 h) are planned.

44 the added burden associated with IP therapy are planned.

45 d studies to demonstrate protective efficacy are planned.

46 Confirmatory trials are planned.

47 re now available and at least another 130000 are planned.

48 conjugates with recombinant diphtheria toxin are planned.

49 program modules have been completed; 2 more are planned.

50 to further evaluate this combination regimen are planned.

51 itive tumors, with minimal residual disease, are planned.

52 luding the quantitative trait loci approach, are planned.

53 Burden testing and functional studies are planned.

54 ting and/or diarrhea; field efficacy studies are planned.

55 ed kidney transplants have occurred, and two are planned.

56 erim analyses, a sample size of 900 patients was planned.

57 formal statistical comparison between groups was planned.

58 for whom an early revascularization strategy was planned.

59 tant changes to the intervention versus what was planned.

60 No formal hypothesis testing was planned.

61 of 1.075), followed by superiority testing, was planned.

62 e sites, all in sites for which radiotherapy was planned.

63 Close follow-up was planned.

64 patients for whom primary surgical resection was planned.

65 = .025, a target sample size of 352 patients was planned.

66 ilated patients in whom fluid administration was planned.

67 r invasive or noninvasive diagnostic testing was planned.

68 whom a switch from natalizumab to fingolimod was planned.

69 Subsequently, a stem-cell transplantation was planned.

70 0% of rehospitalizations were likely to have been planned.

71 ulcerative colitis, and phase 3 studies have been planned.

72 Two interim analyses were planned.

73 e interim analyses with futility assessments were planned.

74 ls (200 mg/m(2) and 150 mg/m(2) twice daily) were planned.

75 Six 28-day cycles were planned.

76 A total of 6 weekly doses of oxaliplatin were planned.

77 ry and axillary lymph node dissection (ALND) were planned.

78 e not blinded, and no inferential statistics were planned.

79 trials to test this possibility are already being planned.

80 servatories to detect Earth-like planets are being planned.

81 ppear adequate for future missions currently being planned.

82 udies with T cell costimulatory blockade are being planned.

83 he movement depended on the type of movement being planned.

84 m this pilot study, a therapeutic regimen is being planned.

85 e conditions and the first human studies are being planned.

86 ly) and bevacizumab (15 mg/kg every 3 weeks) was planned 3 to 6 weeks later for six cycles.

87 Total mesorectal excision was planned 6 weeks after CT-RT.

88 When repair was planned, 84% (21 of 25) were successful.

89 A subgroup analysis was planned a priori in patients with a high level of pr

90 A subset analysis by incision type was planned a priori.

91 f cirrhosis is present or interferon therapy is planned, abstinence from alcohol should be encouraged

92 A priori subgroup analysis was planned according to the location where the study wa

93 An analysis of overall survival is planned after 248 events.

94 A final analysis was planned after 196 deaths and an interim analysis aft

95 is for recurrence-free survival (RFS), which was planned after 227 recurrences.

96 The primary analysis was planned after 305 events.

97 Primary analysis was planned after 470 SREs.

98 f 103 patients in whom an invasive procedure was planned after the stress data, the availability of t

99 ngs indicate that human referential pointing is planned and controlled on the basis of partner-specif

100 When research is planned and interventions are designed to interrupt t

101 -A isoforms with bevacizumab and paclitaxel, is planned and will hopefully provide us with new direct

102 vailable sources, the same implant placement was planned and dose-volume histogram distributions tabu

103 nding internal company documents (i.e., what was planned and what was done).

104 ation was event-driven, and interim analyses were planned and conducted after approximately 120 and 2

105 e developed and country-specific innovations were planned and implemented by the country teams.

106 Most LCs (76%) involved procedures that were planned and performed according to radiographs and

107 personnel sit idle even though staffing has been planned) and a concomitant reduction in percent pro

108 dy was open label, no inferential statistics were planned, and only patients with genotype 1 or 4 inf

109 dy was open-label, no inferential statistics were planned, and sample sizes were small.

110 and support the idea that reaching movements are planned as a hand-centered vector whose extent and d

111 dependence or health-related quality of life are planned as key study outcomes, then the reliability

112 ndpoint, artificial urinary sphincter should be planned as a second stage procedure after stabilizati

113 The effort is planned as a collaboration with the scientific malari

114 The study was planned as a Fleming two-stage design, enabling one

115 It is widely acknowledged that movements are planned at the level of the kinematics.

116 stration of three cycles of ICE chemotherapy was planned at 2-week intervals.

117 Filter retrieval was planned at 3 months from placement.

118 This final OS analysis was planned at 380 deaths.

119 DLC was planned at least 6 weeks after initial antibiotic tr

120 Thienopyridine was planned at randomization in 12,410 (73%).

121 acizumab 1.25 mg/0.05 mL; 3 follow-up visits were planned at week 2, 6, and 12.

122 Longer follow-up is planned because the timeline for LF in this setting s

123 Paclitaxel dose reductions were planned because of the pharmacokinetic interactions

124 cases where pancreatic resection/anastomosis is planned, because of varying ductal anatomy, risk of d

125 Grasping movements are planned before they are executed, but how is the pre

126 ses where a conventional axillary dissection was planned before surgery.

127 vidual patient data analysis of these trials was planned, before their results were known, to assess

128 Elective delivery was planned between 37 weeks 5 days and 38 weeks 6 days

129 uronal activity could reflect movements that are planned but not executed.

130 Conservative treatment was planned but both of them succumbed to the illness.

131 Transarterial embolization was planned but repeat cerebral angiography prior to the

132 o observe localization errors when a saccade is planned, but abruptly aborted just before its executi

133 Reintroduction is planned, but so far, no action has been taken.

134 Six cohorts were planned, but only 3 were enrolled (0.04, 0.15, 0.4

135 Artery-specific SPECT/CT partition modeling was planned by experienced nuclear medicine physicians.

136 m channel blockers in these disorders should be planned carefully.

137 can be managed most effectively if pregnancy is planned, clinicians should discuss the issue of pregn

138 When cataract surgery is planned, corneal topography can be used preoperativel

139 ng urethroplasty and further management will be planned depending upon the presence of any remaining

140 y or as collections (focused libraries), can be planned effectively with retrosynthetic analysis.

141 Until better trials are planned, executed and published, much of what we kno

142 A second cycle of chemotherapy was planned following a 1-week rest.

143 suggest that increased health costs have to be planned for over a long time horizon.

144 had been the subject of much writing and had been planned for, detection of and the appropriate respo

145 Most clinical trials being planned for individuals in the prediagnostic stage

146 uide the organization of clinical trials now being planned for patients with Alzheimer's disease.

147 Follow-up is planned for a minimum of 4 years, with annual visits.

148 Colonoscopic follow-up evaluation was planned for 1 and 3 years after randomization.

149 At randomisation, an invasive strategy was planned for 13 408 (72.0%) of 18 624 patients hospit

150 primary de novo renal transplant recipients was planned for 48 months but terminated early because o

151 This trial was planned for 52-76 weeks, with primary efficacy analy

152 A per-protocol analysis was planned for all children who provided a stool sample

153 uding the kidneys, within 3 h before surgery was planned for all patients.

154 Esophagogastrectomy was planned for approximately 4 weeks after the completi

155 A tunnel technique was planned for both areas in the mandible.

156 Enrollment was planned for cohorts of three patients at doses escal

157 Treatment was planned for eight cycles.

158 Radiotherapy was planned for incomplete response or initial bulk dise

159 Plasmapheresis was planned for up to 3 months after LDLT aiming at main

160 interim analysis of overall survival, which was planned for when approximately 67% (n=330) of 492 ex

161 th detectable Tg and a negative neck US, who were planned for blind (131)I therapy.

162 Patients with chronic pancreatitis who were planned for elective surgical treatment were random

163 Four hundred seventy-five eligible patients were planned for enrollment.

164 paired recipients undergoing allogeneic HSCT were planned for enrolment at 16 transplant centres in t

165 Idealized source distributions were planned for four, eight, 16, 24, 32, and 48 sources

166 SCLC) who either (1) had a new diagnosis and were planned for initial therapy or (2) had developed ac

167 with the DT catheter (study group); patients were planned for PV remapping after 3 months, regardless

168 d resistance to an EGFR kinase inhibitor and were planned for rebiopsy underwent initial blood sampli

169 Fifteen patients were planned for single port transanal surgery.

170 t device patients with stable renal function were planned for this prospective, randomized, open-labe

171 Interim analyses were planned for when 84 patients had been allocated tre

172 Postoperative radiation was planned if R0 resection was not achieved.

173 heory that anticipatory postural adjustments are planned in detail.

174 Also, eye movements are planned in eye coordinates, and the use of similar c

175 If movements are planned in visual space, as indicated from a variety

176 gh risk for stent thrombosis, surgery should be planned in a hospital with cardiac catheterization fa

177 Actions can be planned in either an intrinsic (body-based) reference

178 Similar trials are either underway or being planned in Europe and Asia.

179 e focus on the Morrow Pacific export project being planned in Oregon by Ambre Energy that would ship

180 Increasingly, clinical trials are being planned in patients with mild cognitive impairment

181 Further validation of kSORT is planned in prospective clinical observational and int

182 ents where buccal tooth movement (expansion) is planned in the anterior mandible or involving the max

183 of renal allografts and further discounting is planned in the new United Network of Organ Sharing ki

184 the basis of these results, a clinical trial is planned in which patients bearing a variety of tumor

185 Hepatic surgery was planned in 241 patients but abandoned in nine becaus

186 The stenting procedure was planned in 37% of patients and unplanned in 63% of p

187 through 1 year, and angiography at 13 months was planned in 50 MGuard patients.

188 Sedation was planned in 66 (95.7%) patients and was successful in

189 s for comparison, continuing current therapy was planned in 79% when scans showed no change or a decr

190 ong 104 patients in whom axillary dissection was planned in advance was 10.6% (5/47).

191 h angiographic and 1-year clinical follow-up was planned in all patients.

192 The present substudy, which was planned in the NeoALTTO main protocol, evaluated the

193 d with a higher rate of perinatal death than was planned in-hospital birth (3.9 vs. 1.8 deaths per 10

194 4 shoulder joint and 24 hip joint injections were planned in 12 human cadavers.

195 Two or more categories of systemic therapy were planned in 56% of prostate and 43% of breast cancer

196 Meta-analyses were planned in treatment-naive and treatment-experience

197 cklist recommends a full description of what is planned; it does not prescribe how to design or condu

198 Whenever a 2-stent technique is planned, modified T-stenting appears the most promisi

199 Studies are planned of the expression of ABC transporters in eye

200 primary end points (median, seven per trial) were planned, of which 373 (64.4%; median, five per tria

201 ngle coordinate in the past and only need to be planned one radian ahead.

202 Several trials are planned or are in progress to assess whether minocyc

203 Clinical trials, using these strategies, are planned or have been recently begun and offer hope f

204 In 2001, new programs are planned or in development in India, Argentina, China

205 herapies versus nonreperfused control groups are planned or in progress.

206 exciting clinical trials that are currently being planned or underway.

207 nt groups; no statistical hypothesis testing was planned or conducted.

208 um; n = 527 placebo) for whom imminent birth was planned or expected before 30 weeks' gestation.

209 noma in situ (when breast-conserving surgery is planned) or are pregnant should not undergo SNB.

210 cer, or DCIS (when breast-conserving surgery is planned) or are pregnant should not undergo SNB.

211 ently to enable trials of neuroprotection to be planned, powered and implemented.

212 Therefore, this cross-sectional study was planned, primarily, to determine the ability of Four

213 Enrollment of 230 patients was planned, providing 90% power to observe a 20% differ

214 Future steps were planned regarding 1) recognizing, preventing, and t

215 ts in whom subclavian central line insertion is planned should have both sides examined by ultrasound

216 uses of FLV in children so that services can be planned that promote independence, improve quality of

217 stributed health data networks are currently being planned that could cover millions of people, permi

218 A new clinical trial is planned that will examine whether vitamin E can delay

219 ersus traditional open gastrectomy (OG) have been planned, their surgical outcomes reported but their

220 n patients with trauma and severe hemorrhage is planned.This is an open-access article distributed un

221 United Kingdom and the United States, which are planned to commence shortly.

222 Additional clinical trials are planned to confirm and extend these observations.

223 Further studies are planned to design and synthesize 3CTAs with enhanced

224 Further experiments are planned to determine if facial features or a protect

225 Studies of higher doses are planned to determine the optimal efficacious dose of

226 l 'next-generation' antibody; future studies are planned to determine the potential for affinity-driv

227 Further studies are planned to determine whether the addition of nelarab

228 Also, family studies are planned to establish whether eye-tracking dysfunctio

229 Larger clinical trials are planned to further validate these data.

230 Further studies are planned to identify the mouse nob gene and to evalua

231 campaigns for children younger than 5 years are planned to take place every 3 to 5 years.

232 Clinical trials are planned to test MAb 201, a fully human MAb specific

233 mber of trials have been done, initiated, or are planned to test new immune modulators for cancer the

234 Additional studies are planned to validate the ability of the technique to

235 cushion, so a 1.5-mm minimal distance should be planned to avoid potential nerve injury.

236 The present study has been planned to investigate topical application of a nov

237 Controlled, multicenter trials are being planned to assess the impact of these features on

238 Follow-up is planned to 2 years, and here we present findings at e

239 each region (PRR), is activated when a reach is planned to a visible or remembered target.

240 hether cells would be activated when a reach is planned to an as-yet unspecified goal.

241 The carrier protein is planned to be genetically altered pertussis toxoid.

242 data of UniProt (Universal Protein Resource) is planned to be publicly available on the UniProt web p

243 Enrollment began in 2012 and is planned to continue in multiple stages through 2017.

244 inimal activity in the bladder, further work is planned to correlate imaging findings with histopatho

245 Expanded surveillance is planned to define the dynamics of transmission.

246 ander Philae onboard the Rosetta space probe is planned to detach from the orbiter and soft-land on t

247 Long-term follow-up is planned to determine whether the observed changes are

248 Future clinical study is planned to develop this drug for use in OM management

249 geneous high-risk group, and a phase 3 study is planned to fully assess efficacy.

250 An additional study is planned to fully evaluate safety and efficacy at the

251 our patient are good and life-long follow-up is planned to prevent late complications.

252 In 24 cases, radiotherapy was planned to a clinical target volume consisting of th

253 In 21 cases, radiotherapy was planned to a clinical target volume consisting of th

254 Results: In 24 cases, radiotherapy was planned to a clinical target volume consisting of th

255 One interim analysis was planned to allow the study to stop early for efficac

256 This study was planned to assess whether vitamin D3 is a protective

257 The amount of therapist time in CCBT was planned to be about one-third that in CBT.

258 External validation was planned to be performed on the cohort of the two rec

259 oncerted Action on SIDS (ECAS) investigation was planned to bring together data from these and new st

260 als (RCTs) in this area is small and a trial was planned to compare midazolam and clonidine, two seda

261 f 1,113 evaluable patients per treatment arm was planned to confirm noninferiority with expected CR o

262 etween February 2010 and May 2012; treatment was planned to continue until patients were followed-up

263 Translational research was planned to correlate the expression of apoptotic and

264 controlled phase III trial conducted by SWOG was planned to define the role of mifepristone in the tr

265 The present study was planned to determine that relationship, using cardia

266 Finally, a set of in vitro studies was planned to dissect the biological functions exerted

267 This study about the prophylactic treatment was planned to focus on the effect in the generation of

268 The present study was planned to investigate the therapeutic actions of 1-

269 This study was planned to investigate whether anti-TGF-beta mitigat

270 MATERIAL/METHODS: The prospective study was planned to qualify 50 children treated for long bone

271 tween sequences duplicated in the 'in step', was planned to replace the sequences encoding the putati

272 An experimental design was planned to study three factors affecting the test: t

273 e final analysis of recurrence-free survival was planned to take place after 214 or more events of di

274 This final efficacy analysis was planned to take place after 940 DFS events.

275 randomly assigned 4752 patients in whom CABG was planned to undergo the procedure off-pump or on-pump

276 A placebo group of 14 subjects was planned to verify placebo response rate and estimate

277 Follow-up telephone calls and clinic visits were planned to alternate at 3-month intervals after ran

278 Approximately 2,522 patients were planned to be enrolled < or =12 hrs after the onset

279 No corticosteroids were planned to be given after the first week postoperat

280 05 and beta = .10, 190 p53-positive patients were planned to be randomly assigned to detect an absolu

281 Our treatments were planned to deliver the maximally tolerated radiatio

282 the resolution of deletion mapping, screens were planned to distribute deletion breakpoints evenly a

283 Multiple sensitivity analyses were planned to examine the impact of each assumption on

284 Analyses were planned to have a minimum median follow-up of 15 mo

285 Baseline and 6 follow-up visits were planned to record disease activity and collect bloo

286 The approach to the cortex was planned using an MRI-based 3D model of the sheep's b

287 Dose escalations were planned using a modified Fibonacci sequence.

288 (IOPs) >/= 18 mmHg in whom an aqueous shunt was planned were randomized to an AGV or a BGI.

289 whom glaucoma drainage implant (GDI) surgery was planned were randomized to implantation of an AGV or

290 Meta-analysis was planned where clinical study heterogeneity allowed.

291 d prediagnosis Huntington disease trials can be planned with PFS, and there is evidence of generaliza

292 inical trials that are either in progress or being planned with the aim of preventing these disorders

293 ee consecutive ALDLTs (71 right and 12 left) were planned with 3D CASP.

294 acy analysis of TC versus the TaxAC regimens was planned, with invasive disease-free survival (IDFS)